Blog

Nelson Advisors partner Lloyd Price was interviewed by Healthcare Business International for their 'Doctolib buys Medicus and enters the UK' story.Source: <a href="https://www.healthcarebusinessinternational.com/doctolib-buys-medicus-and-enters-the-uk/" data-mce-href="https://www.healthcarebusinessinternational.com/doctolib-buys-medicus-and-enters-the-uk/">https://www.healthcarebusinessinternational.com/doctolib-buys-medicus-and-enters-the-uk/</a>Lloyd Price, partner at M&amp;A advisory firm Nelson Advisors, tells HBI the UK offers significant scaling potential. “The UK market, with its 6,500 GP practices and 63.8 million patients, offers the scale required to offset the high customer acquisition costs (CAC) associated with recruiting doctors across different regulatory environments in Germany and Italy. By becoming the “Operating System” for NHS primary care, Doctolib can capture recurring SaaS revenues while leveraging its AI modules to drive Average Revenue Per User (ARPU) growth, Price says.Doctolib reached Annual Recurring Revenue (ARR) of €348 million (~$409.6 mn) in 2024, growing 22.5% YoY. Its revenue was 99% subscription-based from healthcare practitioners, with Germany contributing nearly 20% of ARR and 28% of new revenue inQ1 2025.Growth has slowed in France and Germany following regulatory changes, while Italy and other European markets are still maturing. “The key question is how they continue to expand their total addressable market in Europe,” Price adds.“The UK healthcare software market is competitive but still under-penetrated in areas like workflow and patient access. It is ‘winnable but expensive’ for a new entrant,” Price explains. The broader UK digital health market is large and growing rapidly, with estimates in the tens of billions and a projected high-teens to low-twenties CAGR through 2030–2035. Core EPR and primary care software is highly concentrated, with high switching costs and long deployment cycles. In contrast, Price says areas such as AI analytics, remote monitoring, and virtual care are more fragmented, with multiple cloud-native entrants integrating via APIs. Investor interest and expansion Doctolib’s UK performance will hinge on execution of its go-to-market strategy, particularly NHS alignment, competition with entrenched incumbents, and proving clear incremental value beyond existing systems, as per Price. Market sources see the company as a strong IPO candidate within the next 18 months. It recently completed a €300 million (~$345 million) secondary share sale in April 2026, valuing the business at €3.6 billion (~$4.24 billion). Price argues that its UK expansion adds “the scale and clinical depth necessary to sustain a public valuation in the range of $6 billion to $8 billion (~€5.1 bn to €6.8 bn).”

Nelson Advisors interviewed by Healthcare Business International for their 'Doctolib buys Medicus and enters the UK' story

Nelson Advisors partner Lloyd Price was interviewed by CFNews for their 'Doctolib enters the UK Market' story.CFNEWS (Corporate Finance News) is the leading independent digital media and data provider dedicated to the French corporate finance, private equity, and M&amp;A ecosystem.Founded in 2007, it has established itself as the "Gold Standard" for professionals tracking deal flow in the French-speaking market.Core Focus Areas The publication covers a broad spectrum of the financial landscape, specifically targeting:Private Equity: Extensive coverage of LBOs (Leveraged Buyouts), growth capital (Capital Développement), and venture capital (Capital Innovation).M&amp;A: Detailed reporting on mergers, acquisitions, and corporate divestitures across all sectors.Source: <a href="https://www.cfnews.net/L-actualite/International/Operations/M-A/Majoritaire/Doctolib-s-offre-une-porte-d-entree-au-Royaume-Uni-692715">https://www.cfnews.net/L-actualite/International/Operations/M-A/Majoritaire/Doctolib-s-offre-une-porte-d-entree-au-Royaume-Uni-692715</a>'To be able to serve general practitioners with software, you need to have all the NHS certifications. And we are the first EPR (Electronic Patient Record) provider in England to have obtained them all in the last 25 years." “For Lloyd Price of Nelson Advisors, a British boutique specializing in M&amp;A transactions in the healthtech sector, ‘what Doctolib has acquired is infrastructure, and speed. Doctolib is the train, and now they can go very fast because they have the tracks.’ The London-based company assures that it will continue to operate with its British teams under the leadership of its CEO, Emile Axelrad, who until now held a controlling stake in the startup through his personal holding company, Axe Ventures Ltd.The final step before the IPO?”With 3,000 employees, Doctolib already serves over 520,000 healthcare professionals, including 40,000 general practitioners, and 90 million patients in Europe. The French Tech champion announced it will achieve profitability for the first time in 2025. It also claims 30% growth and €422 million in ARR for the same year. Its valuation, at €5.8 billion in 2022, was, however, revised downward to €3.6 billion during a secondary funding round in April 2026.&nbsp;What external growth strategy does Doctolib pursue now? Its main competitor, the Polish company DocPlanner, funded by Goldman Sachs, Piton Capital, and Point Nine, already operates in 13 countries in Europe and Latin America. This expansion into the UK could, in any case, constitute a final capital step towards an IPO. "In my opinion, it's the last piece of the puzzle," says Lloyd Price.

Nelson Advisors interviewed by CFNews for their 'Doctolib enters the UK Market' story

Nelson Advisors has been invited to Judge the UCL GBSH Dragons' Den Final 2026 taking place on June 24th 2026.&nbsp;The UCL GBSH Dragons’ Den Final is an annual live pitching competition where UCL Global Business School for Health students pitch healthcare start‑ups to a panel of “Dragons” (investors and entrepreneurs), competing for cash prizes and a year of mentoring.What the event isThe competition is run by UCL’s Global Business School for Health as a flagship entrepreneurship event focused on innovations that improve healthcare delivery and outcomes. It is a live, in‑person evening pitching event, typically held in late June at UCL, with an audience of students, staff, and external guests. Who can enter The most recent editions are open to all GBSH postgraduate and MBA Health students with innovative business ideas in any part of the health ecosystem (digital health, biotech, pharma, health management, public health, etc.). The inaugural 2023 event was broader, allowing any UK postgraduate student with a healthcare business idea to compete, not just those from UCL GBSH. Format and prizes Applicants go through a multi‑round selection process, with several rounds of screening before reaching the final live pitch. At the final, 8–10 shortlisted teams pitch their ideas to a panel of Dragons drawn from healthcare investment, entrepreneurship, and industry leadership. All finalists receive a cash contribution to help start their ventures, and the winning team receives a larger cash prize (recently around £4,000) plus a year of expert mentoring. Recent final and winner In the third annual Dragons’ Den Final (2025), five finalist teams pitched healthcare innovations spanning digital health, public health, and biotech. The winning team, Lumina, presented an AI‑powered perinatal mental health platform, which impressed the judges for its scalability, clinical relevance, and existing pilot activity in the United States. Judges highlighted Lumina’s potential for industry partnerships and policy impact, and the founders described the competition as transformative for turning academic work into a real‑world venture. Why it matters The Final gives health‑focused postgraduates hands‑on experience in venture creation: refining a business model, pitching to investors, and receiving critical feedback. It also acts as a networking hub, connecting student founders with healthcare investors, operators, and mentors who can support commercialisation of their ideas beyond the university setting.

Nelson Advisors invited to Judge the UCL GBSH Dragons' Den Final 2026

The European healthcare technology landscape has reached a definitive inflection point in 2026, transitioning from a period of speculative, venture subsidised fragmentation into a disciplined era defined by industrial maturity and strategic consolidation. At the vanguard of this transformation is Doctolib, a platform that has successfully navigated the post-pandemic recalibration to emerge as the dominant digital health infrastructure provider across France, Germany, and Italy. The acquisition of the London-based startup Medicus Health in May 2026 represents the final, critical piece of the company’s strategic "jigsaw" ahead of its anticipated initial public offering (IPO). This expansion into the United Kingdom is not merely a geographic addition but a sophisticated play to integrate into the National Health Service (NHS) ecosystem, leveraging a rare window of regulatory openness in the British primary care IT market. &nbsp; The strategic move comes at a time of significant regulatory flux in Doctolib’s largest markets. In Germany, the implementation of the Digital-Gesetz (DigiG) and the Health Data Use Act (GDNG) has mandated a shift toward interoperability and performance-based reimbursement, placing intense pressure on legacy business models while creating a "compliance moat" for technologically agile players.&nbsp; &nbsp;&nbsp; Simultaneously, the success of the Dottori.it acquisition in Italy has provided a blueprint for cross-border expansion, proving that the localized "evangelization" of healthcare professionals can overcome fragmented market conditions.&nbsp; &nbsp;&nbsp; By securing a foothold in England’s GP practice network through Medicus Health, Doctolib is positioning its artificial intelligence (AI) and "Operating System" vision at the heart of European clinical workflows, aiming to replace administrative friction with a unified, data-driven environment.Click here to read our full report <a href="https://www.healthcare.digital/single-post/doctolib-s-acquisition-of-medicus-health-to-enter-the-uk-market">https://www.healthcare.digital/single-post/doctolib-s-acquisition-of-medicus-health-to-enter-the-uk-market</a>Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. <a href="http://www.nelsonadvisors.co.uk">www.nelsonadvisors.co.uk</a>Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis &amp; predictions @ <a href="https://www.healthcare.digital">https://www.healthcare.digital</a>#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTechNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NT<a href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a><a href="mailto:paul@nelsonadvisors.co.uk">paul@nelsonadvisors.co.uk</a>

Doctolib’s acquisition of Medicus Health to enter the UK market

Milken Institute Global Conference 2026The Milken Institute Global Conference 2026, held May 4-6 th in Beverly Hills, highlighted several breakthrough healthcare technology and AI themes centered on translating innovation into scalable, resilient systems. The conference emphasized precision medicine, artificial intelligence, next-generation therapeutics, and cross-sector collaboration as strategic priorities at the intersection of innovation, investment, and policy.AI-Accelerated Discovery and Development AI-enabled drug discovery emerged as a major theme, with AI positioned to accelerate drug development through deeper collaboration between technology and pharmaceutical companies. The conference featured discussions on how AI is transforming the global healthcare ecosystem, from turbo-charging drug development to benefiting healthcare delivery and access, with stakeholders intensifying AI adoption to improve efficiency, accuracy, affordability, and trust. Sessions examined separating fact from fiction regarding AI benefits while minimizing risks in defining a new age of healthcare.Multimodal Data Platforms Multimodal data platforms represented a significant innovation theme, with technologies integrating imaging, EHR data, lab values, clinical notes, and genomics to enable more accurate, context-aware clinical decisions. The conference highlighted how multimodal AI systems combine pathology, radiology, omics, and clinical notes to improve predictive performance and identify biomarkers invisible to single-modality approaches. These platforms are creating opportunities to build entirely new categories of healthcare solutions.Next-Generation Diagnostics The conference spotlighted next-generation diagnostics as opening new territory for health investing, with emphasis on AI-enabled diagnostic capabilities and early detection tools. Discussions covered how diagnostic performance increasingly depends on AI rather than just hardware or assays, with differentiation shifting toward multimodal intelligence solutions that combine imaging, EHR, lab, and genomic data into integrated views. Point-of-care diagnostics were discussed as critical for improving healthcare delivery and facilitating antimicrobial stewardship.Innovative Care Models and Regulatory Challenges The conference addressed innovative care models alongside significant headwinds facing the industry, including FDA uncertainty, pricing policies, and tariffs impacting the translation of advances into practical impact. Sessions examined what will be needed to foster innovations poised to define the next decade of opportunity across the health ecosystem. The regulatory environment featured prominently, with discussions on FDA staffing concerns balanced against support for accelerated approval pathways for rare disease treatments.Healthcare Investment and Cross-Sector Collaboration Investment themes centered on how private capital is emerging as a critical lever for transforming health systems globally, with panels examining where compelling opportunities lie, how risk is being priced and structured, and requirements to move capital from commitment to impact. The conference reinforced the role of cross-sector collaboration in shaping the future of care delivery worldwide, with healthcare positioned as a strategic focus at the crossroads of innovation, investment, and policy.Source: <a href="https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research" data-mce-href="https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research">https://milkeninstitute.org/events/global-conference-2026/program?f%5Btracks%5D=Health+%26+Medical+Research</a>Milken Institute Global Conference 2026The Milken Institute Global Conference is the Institute’s flagship annual convening, bringing together leaders across health, finance, business, technology, philanthropy, and public policy. The 2026 conference focuses on translating recent disruption and innovation into practical solutions for a more sustainable, equitable, and resilient future.It is a unique experience in which individuals with the capital and influence to change the world connect with those whose expertise and creativity are reinventing health, finance, business, technology, philanthropy, industry, and society.The 29th annual Global Conference will convene our diverse and forward-thinking community to tackle these urgent issues and seize opportunities to collectively shape a more sustainable, equitable, and resilient future.&nbsp;Join us as we reflect on the disruptions and innovations of the recent past and translate lessons learned into building meaningful, healthy, and prosperous lives for all.Follow the conversation with #MIGlobal

Key Healthcare Technology and Healthcare AI themes from Milken Conference 2026

The global healthcare technology and medical technology sectors have transitioned into a definitive era of disciplined industrial maturity as of the first half of 2026. This period, characterised as the emergence of HealthTech 2.0, represents a structural shift from the speculative, volume-driven dealmaking of the pandemic era toward high-value, transformative transactions grounded in fundamental business metrics.&nbsp; &nbsp;&nbsp; In this new phase, valuation is no longer merely a reflection of prospective market capture; instead, it is predicated on a company’s deep integration into clinical pathways, its regulatory fortitude under a maturing global framework and its capacity to deliver a sustainable, measurable return on investment to health systems facing unprecedented fiscal constraints.&nbsp; &nbsp;&nbsp; As 2026 unfolds, the market is witnessing a selective recovery where high-quality assets with defensible moats command premium multiples, while those lacking operational leverage or regulatory readiness face significant compression.To read our full report please click here <a href="https://www.healthcare.digital/single-post/healthtech-and-medtech-m-a-2026-valuation-multipliers">https://www.healthcare.digital/single-post/healthtech-and-medtech-m-a-2026-valuation-multipliers</a> &nbsp;

Nelson Advisors

Blog

Nelson Advisors interviewed by Healthcare Business Intern...

Nelson Advisors interviewed by CFNews for their 'Doctolib...

Nelson Advisors invited to Judge the UCL GBSH Dragons' De...

Doctolib’s acquisition of Medicus Health to enter the UK ...

Key Healthcare Technology and Healthcare AI themes from M...

HealthTech and MedTech M&A 2026 Valuation Multipliers